Company overview
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing GSK with another company.
| Daily close (USD) | $46.54 |
| Market capitalization (USD) | $100,420,405,755.02 |
| Price / earnings (TTM) | 12.11 |
| Price / book | 4.68 |
No matching rows. Clear the filter to see all records.
Read GSK's valuation metrics
Company size
GSK plc American Depositary Shares (Each representing two Ordinary Shares)'s recorded market capitalization is $100,420,405,755.02. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
GSK's recorded P/E is 12.11: about $12.11 of share price for each $1 of trailing annual earnings per share. Compare that multiple with earnings growth and companies in the same business.
Price relative to book equity
GSK's recorded price-to-book ratio is 4.68. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research GSK plc American Depositary Shares (Each representing two Ordinary Shares) with Aurora
Use the snapshot above to ask a specific question about GSK. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow GSK's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.